The Texas maker of an embolism-preventing catheter just raised $4 million, according to a regulatory filing.
BiO2 Medical‘s Angel Catheter is meant to prevent pulmonary embolisms in hospitalized patients that carry a high risk of developing the complication – particularly those with severe head and spinal injuries. For such injuries, anticoagulants can be dangerous – hence the need for an alternative, the company says.
Embolisms can be costly, after all – and devastating to a patient’s health. A recent survey of pulmonary embolism costs placed it at about $9,000 per patient – on top of the care the inpatient was already receiving in the hospital.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Studying Brigham & Women’s Hospital over the course of eight years, the study found that “an average of 160 patients with pulmonary embolism were admitted each year, requiring an annual hospital expense ranging from $884,814 to $1,866,489.”
The filing shows the startup’s after $10 million in total for the round; the $4 million has thus far been raised from a single investor. BiO2 Medical has raised more than $35 million since it was founded in 2006.
That said, the device is still not FDA-cleared. It has a CE mark for sale in Europe, though it’s still in investigational use in the U.S. It is however in the midst of a 150-patient, multicenter trial to determine the efficacy of the device. It’s indicated for up to 30 days of use.